Table 1 Clinical characteristics
Part A: Whole group
MeasurementWhole groupNo progressionProgressionp Value
(n = 89)(n = 53)(n = 36)
median (IQR)median (IQR)median (IQR)
Age (years)36.5 (29.6; 43.5)34.2 (29.4; 42.3)39.3 (33.2; 47.6)ns
Sex (M/F)34/5516/3718/18ns*
Disease type (relapse-onset/progressive-onset)74/1549/425/110.008*
Use of DMT (yes/no)21/6814/397/29ns*
Disease duration (years)1.6 (0.7; 4.1)1.5 (0.6; 3.7)2.6 (0.8; 4.5)ns
EDSS baseline2.0 (2.0; 3.0)2.5 (2.0; 3.0)2.0 (1.6; 3.0)ns
EDSS follow-up2.5 (2.0; 3.5)2.0 (1.8; 3.0)3.5 (3.0; 5.4)<0.001
Progression rate (change EDSS/year)0.2 (0.0; 0.5)0.0 (−0.3; 0.3)0.7 (0.5; 1.0)<0.001
Part B: Relapse-onset group
MeasurementWhole groupNo progressionProgressionp Value
(n = 74)(n = 49)(n = 25)
median (IQR)median (IQR)median (IQR)
Age (years)35.5 (29.4; 42.6)34.2 (29.4; 42.8)35.8 (27.5; 42.6)ns
Sex (M/F)23/5114/359/16ns*
Use of DMT (yes/no)21/5314/357/18ns*
Disease duration (years)1.7 (0.6; 4.4)1.5 (0.6; 3.8)3.7 (0.7; 4.8)ns
EDSS baseline2.0 (1.9; 2.6)2.5 (2.0; 3.0)2.0 (1.5; 2.5)0.021
EDSS follow-up2.5 (2.0; 3.0)2.0 (1.5; 3.0)3.0 (2.5; 4.0)<0.001
Progression rate (change EDSS/year)0.2 (0.0; 0.5)0.0 (−0.3; 0.2)0.7 (0.5; 1.0)<0.001
  • Progression, increase in EDSS of at least 1 point ; p value, Mann–Whitney U test was used to test for differences between the progression and the no progression group

  • IQR, interquartile range (25%; 75%)

  • *Pearson chi-square

  • DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; F, female; M, male.